Jasper Therapeutics 15min chart shows KDJ Golden Cross, Bullish Marubozu formation.

According to the 15-minute chart for Jasper Therapeutics, a bullish technical indicator, the KDJ Golden Cross, has been triggered, accompanied by a Bullish Marubozu at 07/14/2025 15:45. This suggests a shift in momentum towards an upward trend, with a potential for further price appreciation. The control of buyers in the market is evident, and it is likely that the bullish momentum will continue.

Jasper Therapeutics (JSPR) has experienced significant volatility in its stock price following the company's announcement of a strategic reorganization. The biotechnology firm, which specializes in the development of experimental drugs, has decided to reduce its workforce by approximately 50% and halt most of its clinical and preclinical programs. This move is aimed at extending its cash runway and focusing resources on its experimental drug, Briquilimab, which is being tested as a treatment for chronic urticaria [1].

The company's stock price has been on a downward trend, with shares down 5.6% to $2.85 following the announcement. This comes after a significant decline of 86.2% year-to-date (YTD) as of the last close. The technical analysis suggests that JSPR is within a falling trend, with several negative signals indicating a weak performance in the near term [2].

Analysts have mixed views on the stock. While some analysts have issued positive ratings, others have expressed caution. For instance, Oppenheimer and UBS have issued "Outperform" and "Buy" ratings, respectively, while BMO Capital has set a target price of $4.0. However, other analysts like BTIG have set a target price of $20.0, indicating a more optimistic view [3].

Despite the challenges, the company has appointed Dr. Daniel Adelman as the Acting Chief Medical Officer, replacing Dr. Edwin Tucker. This change brings experienced leadership to the company, which may enhance its efforts in drug development [3].

Looking ahead, investors should closely monitor the company's progress in its clinical trials for Briquilimab and the impact of the workforce reduction on its operational efficiency. The company plans to share additional data from its BEACON and open-label extension studies later this year, which could provide further insights into the potential of its experimental drug [1].

References:
[1] Reuters. (2025). Jasper Therapeutics falls after halting clinical programs. Retrieved from https://www.tradingview.com/news/reuters.com,2025:newsml_L6N3T60LY:0-jasper-therapeutics-falls-after-halting-clinical-programs/
[2] Intellectia.ai. (2025). Stock forecast for JSPR. Retrieved from https://intellectia.ai/stock/JSPR/forecast
[3] Nasdaq. (2025). Jasper Therapeutics announces 50% workforce reduction and leadership change. Retrieved from https://www.nasdaq.com/articles/jasper-therapeutics-announces-50-workforce-reduction-and-leadership-change-enhance-focus